Alumis, Inc. (ALMS)
7.98
+0.08
(+1.01%)
USD |
NASDAQ |
Sep 22, 10:01
Alumis Total Long Term Debt (Quarterly) : 31.60M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 31.60M |
| March 31, 2026 | 31.22M |
| December 31, 2025 | 32.24M |
| September 30, 2025 | 33.38M |
| June 30, 2025 | 34.72M |
| March 31, 2025 | 29.34M |
| December 31, 2024 | 29.16M |
| Date | Value |
|---|---|
| September 30, 2024 | 29.63M |
| June 30, 2024 | 30.05M |
| March 31, 2024 | 30.46M |
| December 31, 2023 | 30.86M |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Johnson & Johnson | 37.34B |
| Corcept Therapeutics, Inc. | 7.504M |
| Aclaris Therapeutics, Inc. | 1.262M |
| BioAge Labs, Inc. | 2.121M |
| ANI Pharmaceuticals, Inc. | 610.49M |